Bedrijfsoverzicht
Oragenics, Inc. is a development-stage biotechnology company based in the United States that specializes in the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The company operates within the broader healthcare sector, specifically focusing on the biotechnology industry, which implies a high-risk, high-reward environment centered on bringing novel synthetic compounds like ONP-002 to market. As of the latest data available, Oragenics, Inc. (OGEN) maintains a market capitalization of $2.61M and employs a workforce of just 3 individuals. These figures indicate that the company is in an early-stage expansion phase with minimal operational scale, where the entire enterprise value rests on the potential future success of its lead product pipeline rather than established commercial revenue streams. The negligible market cap relative to typical publicly traded entities suggests that the company's primary focus is on capitalizing on intellectual property development rather than generating immediate profit or large-scale sales volume.
Financiële gezondheid
The financial statements for Oragenics, Inc. reveal significant operational losses, with a net income of $-9,842,487 over the trailing twelve months, while both revenue and EBITDA are recorded as N/A. The substantial gap between nominal revenue figures and a net loss of nearly $10 million highlights a cost structure dominated by research, development, and administrative expenses typical of a company in the research phase. Free cash flow stands at $-5,746,671, indicating that the company is burning cash rapidly to fund its operations and R&D initiatives, which limits its current financial flexibility and reliance on external capital sources. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting the pre-revenue or early-revenue status where costs far exceed any generated sales. Despite the high cash burn rate, the company holds $8.40M in cash against a debt obligation of $227,348, creating a significant liquidity buffer. The debt-to-equity ratio of 2.75 suggests a leveraged balance sheet structure, yet the current ratio of 5.64 demonstrates robust short-term liquidity, ensuring the company can meet its immediate obligations without distress. Return on Equity is calculated at -243.9% and Return on Assets at -101.4%, metrics that reveal management is currently operating in a negative return environment as it attempts to scale the business and achieve commercial viability.
Waarderingsbeoordeling
Valuation multiples for Oragenics, Inc. present a mixed picture typical of pre-profitability biotechnology firms, with a trailing P/E ratio listed as N/A due to the absence of positive earnings. The forward P/E is reported as -0.06, a figure that mathematically reflects negative earnings expectations or a lack of projected profitability in the near term, distinguishing it from the historical trailing metric. The price-to-book ratio is 0.31, indicating that the market values the company at significantly less than its net asset book value, which often signals a deep discount or high perceived risk regarding asset realization. Both the price-to-sales ratio and the EV/EBITDA multiple are listed as N/A, suggesting that traditional valuation anchors are unavailable and investors must rely on asset-based or risk-based models instead. The stock's 52-week trading range spans from a low of $0.50 to a high of $9.60, providing a wide volatility band for price discovery. The beta of 1.21 indicates that the stock is 21% more volatile than the broader market, meaning price movements are likely to be amplified relative to general market trends.
Growth & Income
Oragenics, Inc. reports N/A for both revenue growth year-over-year and earnings growth year-over-year, reflecting the developmental stage where historical growth rates are not yet established. In the absence of positive earnings growth to offset revenue growth, the company's financial trajectory is entirely dependent on the successful transition from research to commercialization. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are theoretically reinvested into R&D and growth rather than distributed to shareholders. This reinvestment strategy is standard for development-stage companies that prioritize long-term product development over immediate income generation for investors. The overall growth and income profile is characterized by high volatility and zero current income, relying on the potential future value creation of its nasal delivery therapies to eventually support shareholder returns.